Plasmapheresis for Alzheimer's Disease: Benefits and What the Research Shows

Alzheimer's disease affects millions of families worldwide, and the search for effective treatments continues to be one of medicine's most urgent priorities. Among the investigational approaches drawing growing clinical attention is plasmapheresis a blood-filtering procedure that may help slow the progression of Alzheimer's disease by removing harmful proteins from the bloodstream. While still considered experimental, research into plasmapheresis Alzheimer's treatment has produced some of the most promising early results in decades.

This article explores what the current evidence shows, how the procedure may work in the context of Alzheimer's disease, and what patients and caregivers should understand about its potential benefits and limitations.

‍What Is Alzheimer's Disease?

Alzheimer's disease is a progressive neurodegenerative condition characterized by the accumulation of two abnormal protein structures in the brain: amyloid beta plaques and tau tangles. These deposits disrupt communication between neurons and trigger chronic inflammation, gradually impairing memory, language, reasoning, and daily functioning. It is the most common cause of dementia, accounting for an estimated 60-80% of cases.

Currently available treatments can help manage symptoms, but none have been shown to halt or reverse neurodegeneration. This has fueled interest in disease-modifying therapies - approaches that target the underlying biology of the disease rather than its symptoms.

How Plasmapheresis Works

Plasmapheresis, also known as therapeutic plasma exchange (TPE), is a procedure in which blood is withdrawn from the body, the plasma is separated from blood cells, and fresh plasma or albumin solution is infused as a replacement. The treated blood is then returned to the patient.

For a detailed overview of how plasmapheresis works, including its established uses in autoimmune and neurological conditions, see our dedicated guide.

‍The Peripheral Sink Hypothesis: How Plasmapheresis May Help Alzheimer's‍

The theoretical basis for plasmapheresis Alzheimer's research and specifically for plasma exchange Alzheimer's disease treatment rests on what researchers call the peripheral sink hypothesis (Zhang & Lee, Neuroscientist, 2011).

Amyloid beta (AОІ) the protein fragment that accumulates in Alzheimer's brains is not confined to the central nervous system. It also circulates in the bloodstream, where approximately 90-95% of plasma AОІ is bound to albumin. According to the peripheral sink hypothesis, there exists a dynamic equilibrium between brain and blood AОІ levels. By removing AОІ-laden plasma and replacing it with fresh albumin, TPE may:

1. Reduce peripheral AОІ concentrations creating a concentration gradient that encourages AОІ to exit the brain across the blood-brain barrier.

2. Replenish functional albumin  fresh albumin has neuroprotective properties, anti-inflammatory effects, and enhanced AОІ-binding capacity compared to the oxidized, dysfunctional albumin found in older adults with Alzheimer's

This dual mechanism reducing toxic protein burden while infusing neuroprotective albumin forms the foundation of current clinical research (Cantero-Fortiz & Boada, Front Neurol, 2024).

For context on how this relates to broader longevity research, see our article on the [longevity benefits of plasma exchange](/blog/plasmapheresis-longevity-anti-aging-research).

‍What the Research Shows: The AMBAR Trial and Beyond

‍The AMBAR Randomized Controlled Trial (2020)

The most significant clinical evidence for plasmapheresis Alzheimer's treatment comes from the AMBAR (Alzheimer's Management by Albumin Replacement) trial a phase 2b/3 randomized, controlled study involving 347 patients with mild-to-moderate Alzheimer's disease.

Published in Alzheimer's & Dementia in 2020, the trial found that patients receiving plasma exchange with albumin replacement experienced (Boada et al., Alzheimers Dement, 2020):

• 52% less functional decline on activities of daily living assessments compared to placebo

• 66% less cognitive decline on cognitive rating scales

• Among patients with moderate-stage Alzheimer's (MMSE score 18-21), outcomes were even more pronounced: 61% less decline on both cognitive and functional measures

• Effects on dementia severity and global impression scales ranged from 71% to 100% less decline versus the control group

The treatment protocol involved six intensive weekly sessions followed by monthly maintenance sessions over 14 months.

‍Scoping Review of AMBAR Program Data (2024)

A 2024 scoping review examining seven studies from the AMBAR program found consistent evidence supporting the approach (Cantero-Fortiz & Boada, Front Neurol, 2024). Across studies, patients showed significant slowing of cognitive decline, better preservation of hippocampal volume on neuroimaging, improved brain perfusion metrics, and favorable neuropsychiatric outcomes.

Real-World Evidence (2025)

A 2025 prospective cohort study examined outcomes for plasmapheresis for Alzheimer's patients in routine clinical settings (Taragano et al., J Alzheimers Dis, 2025). Among 32 patients completing 514 procedures, MMSE scores showed 45% less decline compared to historical controls, with 88% reduction in immediate recall deterioration and 74% reduction in delayed recall decline. Language and executive function also showed protective benefits.

Benefits Observed in Clinical Research‍

Based on available evidence, plasmapheresis Alzheimer's clinical research has associated the treatment with the following potential benefits for patients:

• Slowed cognitive decline reduced deterioration in memory, language, and executive function

• Improved functional ability  better preservation of activities of daily living

• Neuroimaging changes preservation of hippocampal volume and improved cerebral blood flow

• Neuropsychiatric stabilization favorable outcomes on behavioral and mood measures

• Greatest benefit in moderate-stage disease patients with moderate Alzheimer's appeared to respond better than those in the mild stage

These are associations observed in clinical research contexts, not guarantees of individual outcomes.

Safety and Side Effects‍

The safety profile of TPE in Alzheimer's trials has been encouraging. In the real-world study, approximately 81.5% of procedures were completed without complication (Taragano et al., J Alzheimers Dis, 2025). When adverse events did occur, they were mild-to-moderate and predominantly related to venipuncture. No severe adverse events were reported.

General TPE-related risks include (Sergent & Ashurst, StatPearls, 2023):

• Transient hypotension

• Hypocalcemia (when citrate anticoagulation is used)

• Allergic or transfusion-related reactions to replacement fluids

• Infection risk at IV access sites

Risks and individual suitability should be evaluated by a qualified healthcare team.

Important Limitations and Current Status‍

Patients and caregivers considering plasmapheresis Alzheimer's options should understand several important limitations of the current evidence:

• Not FDA-approved for Alzheimer's disease TPE remains investigational in this context

• Not an ASFA-listed indication  the American Society for Apheresis has not classified Alzheimer's as an established TPE indication (Connelly-Smith et al., J Clin Apher, 2023)

• Evidence primarily from one research program  much of the data comes from the AMBAR trial and related studies by the same investigator group

• Biomarker confirmation gap approximately 28% of AMBAR participants lacked confirmed amyloid brain pathology, which may have diluted results (Imbimbo et al., Alzheimers Dement Transl Res, 2020)

• Larger trials needed  "larger, longer, and fully blinded studies in patients with biomarker-confirmed brain AОІ pathology are needed" before clinical adoption (Imbimbo et al., 2020; Rohrer et al., Transfus Med Rev, 2023)

‍Key Takeaways‍

• Plasmapheresis Alzheimer's research is advancing, with the AMBAR trial showing 52% less functional decline and 66% less cognitive decline vs. placebo

• The peripheral sink hypothesis suggests reducing peripheral amyloid beta where ~90-95% is albumin-bound - may draw AОІ out of the brain

• Real-world data from 2025 supports AMBAR findings: 45% less MMSE decline and significant memory preservation

• Benefits appear greatest in patients with moderate-stage Alzheimer's disease

• TPE remains investigational for Alzheimer's not FDA-approved or standard of care

• Larger, biomarker-confirmed trials are needed before definitive recommendations can be made

Frequently Asked Questions‍

Is plasmapheresis approved for Alzheimer's disease?‍

No. As of 2026, plasma exchange Alzheimer's disease treatment is not FDA-approved. It remains investigational. The American Society for Apheresis does not currently list Alzheimer's as an established TPE indication (Connelly-Smith et al., J Clin Apher, 2023).

What did the AMBAR trial show?‍

The AMBAR phase 2b/3 trial (n=347) found that patients receiving plasma exchange with albumin replacement experienced 52% less functional decline and 66% less cognitive decline compared to placebo over 14 months. Patients with moderate-stage Alzheimer's showed the most pronounced benefit (Boada et al., Alzheimers Dement, 2020).

How does plasma exchange affect amyloid beta in Alzheimer's?

According to the peripheral sink hypothesis, approximately 90-95% of circulating amyloid beta is bound to albumin in the blood. Removing this amyloid-laden plasma and replacing it with fresh albumin may reduce peripheral AОІ levels, creating a gradient that draws AОІ out of the brain (Zhang & Lee, Neuroscientist, 2011).

Who might benefit most from plasmapheresis for Alzheimer's patients?‍

Current evidence suggests that patients with moderate-stage Alzheimer's (MMSE approximately 18-21) may respond better than those with mild-stage disease. Patients with biomarker-confirmed amyloid brain pathology are most likely to be appropriate candidates (Imbimbo et al., Alzheimers Dement Transl Res, 2020).

How many sessions of plasmapheresis are needed for Alzheimer's?‍

The AMBAR protocol involved six intensive weekly sessions followed by monthly maintenance sessions over a 14-month period. The optimal frequency and duration for clinical use have not yet been established (Boada et al., Alzheimers Dement, 2020).

What are the risks of plasmapheresis for Alzheimer's patients?‍

In trials, TPE was generally well-tolerated  approximately 82% of procedures were uneventful. Mild adverse events included venipuncture-related issues. General TPE risks include transient hypotension and hypocalcemia. No severe adverse events were reported in the real-world study (Taragano et al., J Alzheimers Dis, 2025).

How does plasmapheresis for Alzheimer's compare to other treatments?‍

Currently available Alzheimer's treatments (cholinesterase inhibitors, memantine, anti-amyloid antibodies) address different mechanisms. TPE targets peripheral amyloid burden and albumin function  a distinct approach not shared by existing pharmacological options. Direct comparative trials have not been conducted, and TPE remains investigational.

References‍

1. Boada M, LГіpez OL, OlazarГ-n J, et al. "A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study." Alzheimers Dement. 2020;16(10):1412-1425. DOI: 10.1002/alz.12137‍

2. Cantero-Fortiz Y, Boada M. "The use of plasma exchange with albumin replacement in the management of Alzheimer's disease: a scoping review." Front Neurol. 2024. DOI: 10.3389/fneur.2024.1443132‍

3. Taragano F, Seinhart D, Epstein P, et al. "A real-world study on the safety and efficacy of therapeutic plasma exchange in patients with Alzheimer's disease." J Alzheimers Dis. 2025;108(1):129-141. DOI: 10.1177/13872877251375430‍

4. Rohrer L, Yunce M, Montine TJ, Shan H. "Plasma Exchange in Alzheimer's Disease." Transfus Med Rev. 2023;37(1):10-15. DOI: 10.1016/j.tmrv.2022.09.005‍

5. Imbimbo BP, Ippati S, Ceravolo F, Watling M. "Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease?" Alzheimers Dement Transl Res Clin Interv. 2020;6(1):e12004. DOI: 10.1002/trc2.12004‍

6. Zhang Y, Lee DHS. "Sink hypothesis and therapeutic strategies for attenuating Abeta levels." Neuroscientist. 2011;17(2):163-“173. DOI: 10.1177/1073858410381532‍

7. Connelly-Smith L, Alquist CR, Aqui NA, et al. "Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue." J Clin Apher. 2023;38(2):77-278. DOI: 10.1002/jca.22043

8. Sergent SR, Ashurst JV. "Plasmapheresis." In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560566/‍